IL2 and neuroblastoma: However, in 2007, the results of the Children’s Oncology Group (COG) ANBL0032 trial were communicated, followed by publication in 2010 [7], demonstrating that two-year event-free survival (EFS) and overall survival (OS) of patients with high-risk neuroblastoma receiving dinutuximab and cytokines (granulocyte-macrophage colony stimulating factor and interleukin-2), in addition to isotretinoin, were significantly higher by 20% and 11%, respectively [7], compared to those patients receiving isotretinoin alone.